1. |
Thulasidas M. Ocular evaluation in patients with chronic kidney disease-a hospital based study[J/OL]. J Ophthalmol, 2018, 3(5): 000164[2018-07-25]. https://www.researchgate.net/publication/328264035. DOI: 10.23880/oajo-16000164.
|
2. |
黄冠南, 苏龙. 玻璃体切除术治疗慢性肾衰竭患者增生性糖尿病视网膜病变[J]. 中华眼外伤职业眼病杂志, 2018, 40(5): 333-336. DOI: 10.3760/cma.j.issn.2095-1477.2018.05.004.Huang GN, Su L. Clinical efficacy of vitrectomy for proliferative diabetic retinopathy in patients with chronic renal failure[J]. Chin J Ocul Traum Occupat Eye Dis, 2018, 40(5): 333-336. DOI: 10.3760/cma.j.issn.2095-1477.2018.05.004.
|
3. |
Diskin CJ, Stokes TJ, Dansby LM, et al. A hypothesis: can erythropoietin administration affect the severity of retinopathy in diabetic patients with renal failure?[J]. Am J Med Sci, 2007, 334(4): 260-264. DOI: 10.1097/maj.0b013e3180a5e8ed.
|
4. |
Kameda Y, Hanai K, Uchigata Y, et al. Vitreous hemorrhage in diabetes patients with proliferative diabetic retinopathy undergoing hemodialysis[J]. J Diabetes Investig, 2019, 11(3): 688-692. DOI: 10.1111/jdi.13161.
|
5. |
中华医学会眼科学会眼底病学组, 中国医师协会眼科医师分会眼底病学组. 我国糖尿病视网膜病变临床诊疗指南(2022年)——基于循证医学修订[J]. 中华眼底病杂志, 2023, 39(2): 99-124. DOI: 10.3760/cma.j.cn511434-20230110-00018.Fundus Disease Group of Ophthalmology Society of Chinese Medical Association, Fundus disease Group of Ophthalmologist Branch of Chinese Medical Doctor Association. Evidence-based guidelines for diagnosis and treatment of diabetic retinopathy in China (2022)[J]. Chin J Ocul Fundus Dis, 2023, 39(2): 99-124. DOI: 10.3760/cma.j.cn511434-20230110-00018.
|
6. |
中华医学会糖尿病学分会微血管并发症学组. 中国糖尿病肾脏病防治指南(2021年版)[J]. 中华糖尿病杂志, 2021, 13(8): 762-784. DOI: 10.3760/cma.j.cn115791-20210706-00369.Microvascular Complications Group of Chinese Diabetes Society. Clinical guideline for the prevention and treatment of diabetic kidney disease in China (2021 edition)[J]. Chin J Diabetes Mellitus, 2021, 13(8): 762-784. DOI: 10.3760/cma.j.cn115791-20210706-00369.
|
7. |
严晓腾, 顾操, 陆培荣. 雷珠单抗辅助玻璃体切除术治疗糖尿病性牵拉性视网膜脱离[J]. 中华眼外伤职业眼病杂志, 2021, 43(3): 221-225. DOI: 10.3760/cma.j.cn116022-20201015-00336.Yan XT, Gu C, Lu PR. Ranibizumab assisted with vitrectomy for the treatment of diabetic tractional retinal detachment[J]. Chin J Ocul Traum Occupat Eye Dis, 2021, 43(3): 221-225. DOI: 10.3760/cma.j.cn116022-20201015-00336.
|
8. |
Estacio RO, Mc Farling E, Biggerstaff S, et al. Overt albuminuria predicts diabetic retinopathy in Hispanics with NIDDM[J]. Am J Kidney Dis, 1998, 31(6): 947-953. DOI: 10.1053/ajkd.1998.v31.pm9631838.
|
9. |
Kim YJ, Kim J, Lee JY, et al. Development and progression of diabetic retinopathy and associated risk factors in Korean patients with type 2 diabetes: the experience of a tertiary center[J/OL]. J Korean Med Sci, 2014, 29(12): 1699[2014-11-21]. https://pubmed.ncbi.nlm.nih.gov/25469073/. DOI: 10.3346/jkms.2014.29.12.1699.
|
10. |
Kameda Y, Saeki T, Hanai K, et al. Is chronic kidney disease affecting the postoperative complications of vitrectomy for proliferative diabetic retinopathy?[J/OL]. J Clin Med, 2021, 10(22): 5309[2021-11-15]. https://pubmed.ncbi.nlm.nih.gov/34830589/. DOI: 10.3390/jcm10225309.
|
11. |
Zhang G, Chen H, Chen W, et al. Prevalence and risk factors for diabetic retinopathy in China: a multi-hospital-based cross-sectional study[J]. Br J Ophthalmol, 2017, 101(12): 1591-1595. DOI: 10.1136/bjophthalmol-2017-310316.
|
12. |
范小娥, 柯屹峰, 任新军, 等. 增生型糖尿病视网膜病变微创玻璃体切割手术后新生血管性青光眼的危险因素分析[J]. 中华眼底病杂志, 2021, 37(1): 15-20. DOI: 10.3760/cma.j.cn511434-20200623-00302.Fan XE, Ke YF, Ren XJ, et al. Risk factors of neovascular glaucoma after pars plana vitrectomy for proliferative diabetic retinopathy[J]. Chin J Ocul Fundus Dis, 2021, 37(1): 15-20. DOI: 10.3760/cma.j.cn511434-20200623-00302.
|
13. |
Takayama K, Someya H, Yokoyama H, et al. Risk factors of neovascular glaucoma after 25-gauge vitrectomy for proliferative diabetic retinopathy with vitreous hemorrhage: a retrospective multicenter study[J/OL]. Sci Rep, 2019, 9(1): 14858[2019-10-16]. https://pubmed.ncbi.nlm.nih.gov/31619708/. DOI: 10.1038/s41598-019-51411-6.
|
14. |
Huang C, Hsieh Y, Yang C. Vitrectomy for complications of proliferative diabetic retinopathy in young adults: clinical features and surgical outcomes[J]. Graefe's Arch Clin Exp Ophthalmol, 2017, 255(5): 863-871. DOI: 10.1007/s00417-016-3579-4.
|
15. |
Yamanouchi M, Mori M, Hoshino J, et al. Retinopathy progression and the risk of end-stage kidney disease: results from a longitudinal Japanese cohort of 232 patients with type 2 diabetes and biopsy-proven diabetic kidney disease[J/OL]. BMJ Open Diabetes Res Care, 2019, 7(1): e000726[2019-11-02]. https://pubmed.ncbi.nlm.nih.gov/31798893/. DOI: 10.1136/bmjdrc-2019-000726.
|
16. |
Zhao XY, Xia S, Chen YX. Antivascular endothelial growth factor agents pretreatment before vitrectomy for complicated proliferative diabetic retinopathy: a meta-analysis of randomised controlled trials[J]. Br J Ophthalmol, 2017, 102(8): 1077-1085. DOI: 10.1136/bjophthalmol-2017-311344.
|
17. |
Lee BJ, Yu HG. Vitreous hemorrhage after the 25-gauge transconjunctival sutureless vitrectomy for proliferative diabetic retinopathy[J]. Retina, 2010, 30(10): 1671-1677. DOI: 10.1097/iae.0b013e3181dcfb79.
|
18. |
Khuthaila MK, Hsu J, Chiang A, et al. Postoperative vitreous hemorrhage after diabetic 23-gauge pars plana vitrectomy[J]. Am J Ophthalmol, 2013, 155(4): 757-763. DOI: 10.1016/j.ajo.2012.11.004.
|
19. |
Sato T, Tsuboi K, Nakashima H, et al. Characteristics of cases with postoperative vitreous hemorrhage after 25-gauge vitrectomy for repair of proliferative diabetic retinopathy[J]. Graefe's Arch Clin Exp Ophthalmol, 2016, 255(4): 665-671. DOI: 10.1007/s00417-016-3522-8.
|
20. |
Watanabe Y, Yuzawa Y, Mizumoto D, et al. Long-term follow-up study of 268 diabetic patients undergoing haemodialysis, with special attention to visual acuity and heterogeneity[J]. Nephrol Dial Transplant, 1993, 8(8): 725-734. DOI: 10.1093/ndt/8.8.725.
|
21. |
Shen Y, Yang C. Extended silicone oil tamponade in primary vitrectomy for complex retinal detachment in proliferative diabetic retinopathy: a long-term follow-up study[J]. Eur J Ophthalmol, 2007, 17(6): 954-960. DOI: 10.1177/112067210701700614.
|
22. |
赵通, 巩迪, 陈宜, 等. 增生型糖尿病视网膜病变患眼玻璃体切割手术联合硅油填充治疗后早期出血的相关影响因素分析[J]. 中华眼底病杂志, 2019, 35(2): 140-144. DOI: 10.3760/cma.j.issn.1005-1015.2019.02.007.Zhao T, Gong D, Chen Y, et al. Analysis of factors on early hemorrhage after vitrectomy with silicon oil tamponade for proliferative diabetic retinopathy[J]. Chin J Ocul Fundus Diseases, 2019, 35(2): 140-144. DOI: 10.3760/cma.j.issn.1005-1015.2019.02.007.
|
23. |
Smith JM, Steel DH. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy[J/OL]. Cochrane Database Syst Rev, 2015(8): CD008214[2015-08-07]. https://pubmed.ncbi.nlm.nih.gov/26250103/. DOI: 10.1002/14651858.cd008214.pub3.
|
24. |
Lu Q, Zou C, Cao H, et al. Preoperative intravitreal injection of ranibizumab for patients with severe proliferative diabetic retinopathy contributes to a decreased risk of postoperative neovascular glaucoma[J]. Acta Ophthalmologica, 2016, 94(4): 414-415. DOI: 10.1111/aos.13019.
|